Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Pontevedra (11)

2023

  1. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

2022

  1. Development of a carbocysteine 10% + urea 5% cream for the topical treatment of congenital ichthyosis

    Farmacia Hospitalaria, Vol. 46, Núm. 2, pp. 51-56

  2. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  3. [Translated article] Effect of Drug Compounding on Quality of Life in Patients With Genodermatoses: A Cross-Sectional Study

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 6, pp. T543-T549

2021

  1. Baricitinib and tofacitinib in patients with rheumatoid arthritis: results of regular clinical practice

    Farmacia Hospitalaria, Vol. 45, Núm. 4, pp. 165-169

  2. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice

    Clinical Therapeutics, Vol. 43, Núm. 4, pp. e111-e121

  3. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis

    Farmacia Hospitalaria, Vol. 45, Núm. 2, pp. 73-76

2020

  1. Re-initiation of treatment with sargramostim in a patient with pulmonary alveolar proteinosis

    European Journal of Clinical Pharmacy, Vol. 22, Núm. 3, pp. 175-177

2018

  1. Anakinra for the treatment of undifferentiated systemic auto-inflammatory disease

    European Journal of Clinical Pharmacy, Vol. 20, Núm. 6, pp. 337-339

  2. Use of plasma exchange as therapeutic tool in clinical practice

    Farmacia Hospitalaria, Vol. 42, Núm. 1, pp. 16-19

  3. pH determination as a quality standard for the elaboration of oral liquid compounding formula

    Farmacia Hospitalaria, Vol. 42, Núm. 6, pp. 221-227